enVVeno Medical Reports Three-Year VenoValve Data

Pivotal SAVVE study results for the VenoValve were presented at the 53rd VEITH Symposium in New York City.

Updated on Nov. 20, 2026 in Heart Disease

Isometric editorial illustration of a rigid tubular valve with stacked leaflet blocks on a flat cream base, in muted oxblood, teal, and cream.
enVVeno Medical reported three-year data from its SAVVE pivotal study showing sustained symptom improvement with its VenoValve at the VEITH Symposium in New York City. AI Illustration. Upload story photo >

enVVeno Medical presented three-year data from its SAVVE pivotal study of the VenoValve at the 53rd VEITH Symposium. The results showed sustained improvement in symptoms of deep venous insufficiency through 36 months.

Why it matters

An estimated 3 million people in the United States suffer from severe deep venous insufficiency, and current treatment focuses mainly on compression therapy and wound care rather than the faulty valves causing the condition. Longer-term valve data and a less invasive next-generation system could expand treatment options for these patients.

The SAVVE study is a single-arm trial in 75 patients across 21 U.S. clinical centers, reporting a 5.8-point average rVCSS improvement at 36 months, with VEINES-QOL up 18 points and VEINES-Sym up 19 points. The extraction does not indicate a comparator arm, and the durability beyond 36 months remains unreported.

The players

enVVeno Medical Corporation

enVVeno Medical is an Irvine, California-based medical device company developing venous valve technologies for chronic venous disease.

Dr. David Dexter

Dr. David Dexter is a vascular specialist with Sentara Vascular Specialists who presented the SAVVE study data.

The details

Improvement in rVCSS was observed as early as three months after implantation and was sustained through 36 months, according to the presentation by Dr. David Dexter of Sentara Vascular Specialists. The enVVe System, a next-generation transcatheter venous valve, is designed to be implanted under light sedation without open surgery, and patients are expected to go home the same day.

Timeline

  1. April 2026: FDA granted Investigational Device Exemption authorization for the TAVVE pivotal study.

  2. November 20, 2026: Three-year SAVVE data was presented at the VEITH Symposium.

  3. Year-end 2026: The company expects to enroll the first patient in TAVVE.

Health Landscape

Current deep venous insufficiency treatment centers on compression therapy and wound care, which manage symptoms without repairing the faulty valves. The VenoValve and enVVe System instead aim to address the valve dysfunction directly through transcatheter implantation.

Patients with severe deep venous insufficiency may eventually have a less invasive option that avoids open surgery and allows same-day discharge, if the enVVe System proves effective. The therapy is still in investigational stages, so current patients will not yet have access to it.

The takeaway

Three-year data suggest the VenoValve's symptom benefits persist, but patients should discuss compression therapy and emerging valve options with their vascular specialist. Investigational devices remain unavailable outside clinical studies until regulatory approval.

What happens next

The company plans to proceed to Part 2 of the TAVVE pivotal study following FDA review and expects first patient enrollment by year-end 2026.

Further reading

Explore more on Heart Disease in the United States.

Source note: This article includes information reported by Hawaii Telegraph.